SCHEDULE 13G/A: Opaleye Management Discloses 5.32% Stake in Protara Therapeutics

Opaleye Management, Inc. has filed an amended Schedule 13G, reporting a beneficial ownership of 5.32% of Protara Therapeutics, Inc.'s common stock as of December 31, 2024.

Summary

• Opaleye Management, Inc. and Opaleye, L.P. collectively reported beneficial ownership of 1,825,000 shares of Protara Therapeutics, Inc. common stock.
• This ownership represents 5.32% of the total outstanding common stock of Protara Therapeutics, Inc.
• The filing indicates that Opaleye Management, Inc. holds shared voting power and shared dispositive power over all 1,825,000 shares.
• The shares were not acquired for the purpose of changing or influencing the control of Protara Therapeutics, Inc., nor are they held in connection with any transaction having that purpose or effect, other than activities solely in connection with a nomination under SEC Rule 240.14a-11.

Sentiment

Score: 5

Explanation: The document is a factual regulatory filing disclosing beneficial ownership. It does not contain information that is inherently positive or negative for the company's operational or financial performance, and explicitly states the shares are not held for control purposes, indicating a passive investment.

Risks

• The filing explicitly states that the securities were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer, mitigating potential risks associated with activist investor involvement.

Future Outlook

NA

Industry Context

This filing is a standard regulatory disclosure by an investment firm, Opaleye Management, Inc., indicating a significant passive stake in a publicly traded biotechnology company, Protara Therapeutics, Inc. Such disclosures provide transparency regarding major shareholdings in the market.

Stakeholder Impact

• Shareholders: Provides transparency regarding a significant institutional investor's stake in the company, potentially influencing market perception and trading activity.

Key Dates

Keywords

Protara Therapeutics, Opaleye Management, Beneficial Ownership, Schedule 13G, SEC Filing, Common Stock, Investment Firm, Shareholding